Indinavir-associated lipodystrophy
Authors:
- Christian AquilinaCAChristian Aquilina
- 1 April 1998
- journal article
- case report
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (6) , F37-F39
Abstract
Lipodystrophies are rare cutaneous disorders characterized by the symmetrical loss of subcutaneous fat from the body surface. The cause of lipodystrophy is not known, but a possible genetic predisposition is likely and either overt diabetes mellitus or insulin resistance are often associated. Case study. Eight patients who developed either partial or generalized lipodystrophy after protease inhibitor therapy. In all eight patients lipodystrophy occurred after 2–12 months of starting indinavir and was not preceded by weight loss or inflammatory skin disease. Short-term follow-up after withdrawal of therapy showed no change in the patients' appearance. One patient developed glycosuria as lipodystrophy became manifest. In three cases glucose tolerance test was performed revealing a high level of insulin between the first and third hour of loading. In our view, lipodystrophy is an unwanted side-effect of protease inhibitor therapy causing noticeable disfigurement.Keywords
This publication has 5 references indexed in Scilit:
- Changes in AIDS incidence for men who have sex with men, United States 1990–1995AIDS, 1997
- Protease inhibitor-associated hyperglycaemiaThe Lancet, 1997
- Partial lipodystrophy in coeliac disease.Gut, 1990
- Disorders of the complement system in lipodystrophyClinical Immunology and Immunopathology, 1977
- Lipodystrophy, pancreatitis, and eosinophilia.Gut, 1975